Community Pharmacies

Shockat Adam Excerpts

Tuesday 2nd June 2026 Westminster Hall

[Shockat Adam (Leicester South) (Ind)]

It is always a pleasure to serve under your chairship, Ms Jardine. I thank the hon. Member for Tiverton and Minehead (Rachel Gilmour) for securing this debate. She, the hon. Member for North Somerset (Sadik Al-Hassan) and all colleagues have dispensed some great ideas today. [Laughter.] Sorry, but it does not end there.

The Minister and Members may be aware—I might not have mentioned it enough—that I am one of the only practising optometrists to be a Member of Parliament, and optometrists share many of the concerns and challenges that our pharmacy colleagues face. I surpass the hon. Member for North Somerset in having been a community-based optometrist for nearly three decades.

I want to address many of the points that have been made. First, our GPs are facing real burnout. There is a lag in the number of GPs who are qualifying and taking up positions. In lower socioeconomic areas, of which there are many in my Leicester South constituency, there are 1,985 patients per GP. There are 300 more patients per GP in those areas and, as has been mentioned, pharmacists really do plug the gap, saving 38 million GP appointments and doing incredible work. The Government’s 10-year health plan is built on the bold premise of shifting care out of hospitals and into our communities. We all support that ambition—of course we do—but we cannot deliver care in the community if we are not allowing community infrastructure to thrive, and that is precisely what is happening to pharmacies at the moment.

Since 2017, England has lost more than 1,400 bricks-and-mortar pharmacies, which is a net loss of 15% of the entire network. In Leicester, five pharmacies have shut down in the last calendar year alone. There are now fewer than 10,000 pharmacies open in England, and nearly 64,000 opening hours a week have disappeared since 2022. Between 2021 and 2025, the sector lost 3,000 full-time equivalent pharmacists. Funding was cut in 2016 and held flat for eight years, and the sector has absorbed real-terms cuts of 30%. Pharmacies, unlike other businesses, cannot pass on their costs to their customers. They cannot manage demand by extending their waiting lists, and 90% to 95% of their income comes from the NHS. They are, in effect, trapped.

We all welcome the £340 million uplift announced for 2026-27 and the decision to begin integrating independent prescribing into Pharmacy First and the Pharmacy Contraception Service. Those are welcome steps, and everything of that nature is going in the right direction. However, NPA analysis shows that 8.9% is needed simply to allow pharmacy budgets to stand still—to absorb the national living wage, employers’ national insurance contributions, inflation and business rates. The settlement is just 1.3 percentage points above that threshold; it does not close the £2 billion funding gap that the NHS’s independent review identified a year ago. Much of the uplift will be swallowed by costs before a single patient sees any benefit.

I am not just here to outline the problems, as there are positives. Community pharmacies represent one of the greatest untapped opportunities in modern healthcare, and I say that as someone who has seen community-based clinical practice at work. Independent prescribing is, as the sector rightly calls it, a generational opportunity. Pharmacists already have the clinical skills. With the right framework and investment, they can manage long-term conditions, initiate and adjust medicines and take pressure directly off GPs—not as a stopgap, but as a genuine, permanent part of the primary care team.

Beyond prescribing, pharmacies are ideally placed to deliver integrated healthcare and lifestyle services, such as smoking cessation, weight management, hypertension case-finding and alcohol interventions. In my experience in community eye care, the closer we embed clinical services in high street settings, the better the uptake by patients who would never otherwise engage with the NHS. Pharmacies are trusted, accessible and visited regularly—far more than any GP surgery.

Medicine optimisation is another point. With an ageing population on complex polypharmacy regimes, pharmacists conducting structured medication reviews can reduce harm, cut millions of pounds in waste and improve outcomes. This is not aspirational; it is proven. We are simply failing to fund it at scale.

I have a repeat prescription for the Minister. First, publish a road map to close the pharmacy funding gap with above-inflation increases—not in one year, but as a sustained multi-year commitment. Pharmacies cannot plan, invest or recruit without it. Secondly, match investment in retained margins with real action on medicine pricing. The UK is an unattractive market for global suppliers, and medicine shortages flow directly from that. That is a patient safety issue. Thirdly, be genuinely ambitious on independent prescribing. The autumn roll-out into Pharmacy First is a start, but we need a shared vision of what full deployment looks like in this Parliament, with the funding to match. Finally, address the workforce crisis by setting out concrete steps to grow the pharmacy workforce in parallel with any expansion of services. New services on the backs of a depleted workforce will fail.